CGON (CG Oncology) Revenue: $5.07 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGON CG Oncology Inc CGON
12 GF Score
Price $71.92
! 5 Warning Signs
View Full Analysis

What is CG Oncology Revenue?

CG Oncology CGON +3.38% 12 Revenue is $5.07 Mil as of Mar. 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

CG Oncology's revenue for the three months ended in Mar. 2026 was $1.08 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $5.07 Mil. CG Oncology's Revenue per Share for the three months ended in Mar. 2026 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06.

During the past 12 months, the average Revenue per Share Growth Rate of CG Oncology was 481.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 0.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 5 years, CG Oncology's highest 3-Year average Revenue per Share Growth Rate was 0.60% per year. The lowest was -61.20% per year. And the median was -30.30% per year.

CG Oncology  (NAS:CGON) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

CG Oncology Revenue Related Terms

CG Oncology Revenue Historical Data

* Premium members only.

The historical data trend for CG Oncology's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology Revenue Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
10.36 0.19 0.20 1.14 4.04

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.00 1.67 2.32 1.08

CGON vs COGT, SRRK, LGND: Revenue Comparison

For the Biotechnology subindustry, CG Oncology's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Revenue distribution charts can be found below:

* The bar in red indicates where CG Oncology's Revenue falls into.


CGON
12GF Score
CG Oncology Inc CGON
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $5.07 Mil mean?
CG Oncology (CGON) has a Revenue of $5.07 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on CG Oncology and its competitors.
Is CG Oncology's Revenue too high?
CG Oncology's current Revenue is $5.07 Mil. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Revenue compare to COGT and SRRK?
CG Oncology's Revenue of $5.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on CG Oncology and its competitors. CG Oncology's current Revenue is $5.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Revenue of $5.07 Mil. The current Revenue is $5.07 Mil. CG Oncology's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For CG Oncology (CGON), the current Revenue is $5.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.92
Price